Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04643366 · ClinicalTrials.gov registry record · Phase 2
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
A Phase 2 study of Rectal Cancer, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT04643366 is a Phase 2 study of Rectal Cancer that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 54 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04643366, a Phase 2 study of Rectal Cancer, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Chemotherapy
Study Locations (3)
Virginia
- Virginia Cancer Institute - Richmond
- Virginia Commonwealth University Massey Cancer Center - Richmond
- VCU Community Memorial Healthcenter - South Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2033-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04643366
The ClinicalTrials.gov registry entry for NCT04643366 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT04643366 reports 3 study locations spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04643366 about?
NCT04643366 is a clinical study titled "Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer". This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
What is the current status of trial NCT04643366?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2021-01-28. Estimated completion is 2033-01-31.
What conditions does trial NCT04643366 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT04643366?
The interventions under investigation include: Radiation Therapy (RADIATION), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04643366?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04643366 being conducted?
This trial has 3 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.